MedicineNews

Mallinckrodt Generic Opioids Maker to Settle Lawsuit by Paying Over $24 Million

Generic opioids maker Mallinckrodt – One of the biggest manufacturers of has settled a lawsuit with two Ohio counties, eliminating the company from the first federal trial over the toll of the opioid crisis.

On Friday Mallinckrodt, a United Kingdom-based interjected the cope with Cuyahoga and Summit counties. Under the settlement, the company would pay a sum of $24 million and donate products, together with some used to treat dependency, worth another $6 million.

The company’s general counsel stated in a statement that resolving the first cases offers it time to work towards a “global resolution” of opioid lawsuits. Almost every state within the U.S. and more than 2,000 local governments are prosecuting drug companies over the disaster. Mallinckrodt stays a defendant in lots of these cases.

The deal makes Mallinckrodt the third firm in recent weeks to announce a cope with the two counties forward of the trial, scheduled to start Oct. 21 in U.S. District Court in Cleveland. Allergan agreed to pay $5 million and Endo Pharmaceuticals $10 million.

Perhaps the best-known producer of prescription opioids, OxyContin maker Purdue Pharma, is negotiating in a try to settle all of the claims towards it. One settlement proposal calls for Purdue to pay between $10 billion and $12 billion and requires that the controlling Sackler family quit ownership.

Opioids, together with prescription drugs and illicit ones such as heroin and fentanyl, have been linked to greater than 400,000 deaths in the U.S. since 2000.

Tags

Felicia Broderick

Felicia is the head of the column Medical Devices. An Electronics Engineer from the University of Michigan, Felicia, before opting for technical writing as a profession, worked at firms such as SEH, Leviton, etc. In 2016, she quit her job at Leviton and started taking writing projects as a freelancer. Gradually, she developed an interest in technical writing, and now leading a column here.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close